Chimerix is a biopharmaceutical company focused on developing medicines for patients living with cancer and other serious diseases. Co.'s three clinical-stage development programs are brincidofovir, an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is under review for regulatory approval in the U.S.; ONC201, which is being investigated in a number of efficacy studies for recurrent H3 K27M-mutant glioma; and dociparstat sodium, which is in development as a potential first-line therapy in acute myeloid leukemia and as a potential treatment for acute lung injury in COVID-19 patients. The CMRX stock yearly return is shown above.
The yearly return on the CMRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CMRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|